Somatic activating ARAF mutations in Langerhans cell histiocytosis

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• The extracellular signal-regulated kinase (ERK) pathway is implicated in Langerhans cell histiocytosis (LCH).
• Somatic activating mutations in BRAF are found in approximately 60% of LCH cases, suggesting other genetic drivers of ERK pathway activation exist.

Purpose of the Study:

• To investigate alternative genetic mutations causing ERK pathway activation in LCH patients with wild-type BRAF.
• To characterize the functional impact of identified mutations on ARAF kinase activity and cellular transformation.

Main Methods:

• Whole exome sequencing was performed on purified LCH cells from three patients.
• In vitro kinase assays were used to assess the activity of wild-type and mutant ARAF.
• Mouse embryo fibroblast transformation assays were conducted to evaluate the oncogenic potential of mutant ARAF.

Main Results:

• One patient with wild-type BRAF harbored compound mutations in the ARAF kinase domain.
• The identified mutant ARAF exhibited significantly higher kinase activity compared to wild-type ARAF in vitro.
• Mutant ARAF demonstrated the ability to transform mouse embryo fibroblasts and its activity was inhibited by vemurafenib.

Conclusions:

• Mutations in ARAF represent a novel genetic cause of ERK pathway activation in LCH.
• Targeted inhibition of the ERK pathway, potentially using BRAF inhibitors like vemurafenib, may be beneficial for LCH patients with ARAF mutations.
• Comprehensive evaluation of ERK pathway abnormalities is crucial for personalized therapeutic strategies in LCH.